Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TiNivo: Tivozanib + Nivolumab in mRCC
NCT03136627Phase 2Completed
- Sponsor
- AVEO Oncology
- Start
- Mar 2017
- Primary completion
- Dec 2017
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tivozanib in renal cell carcinoma (RCC), sponsored by AVEO Oncology. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Mar 2017; status: completed.
02
Drugs
tivozanib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT03136627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03136627.